Renal Survival in Proteinase 3 and Myeloperoxidase ANCA-Associated Systemic Vasculitis

• DOI: 10.2215/cjn.01020113
• Publication Date: 2013-07-12T04:24:22Z
• Authors: Anoek A.E. de Joode; Jan Stephan F. Sa...; Coen A. Stegeman
• Keywords: Renal replacement therapy

This study evaluated predictors for patient and renal survival in patients with ANCA-associated vasculitis (AAV) without involvement.There were 273 consecutive AAV from January 1990 until December 2007 who followed death, loss to follow-up, or 2010. Based on organ involvement, divided into (n=212) nonrenal groups (n=61). The primary end point was ESRD requiring replacement therapy (RRT) transplantation death.Patient significantly better the group compared (hazard ratio, 0.55; 95% confidence interval, 0.33 0.92; P=0.02). In group, worse MPO-ANCA-positive (n=65) PR3-ANCA-positive (n=138) 2.1; 1.11 3.8; P=0.01). Of 48 needed RRT at diagnosis, 11 (23%) died within 6 months 14 (29%) did not regain function. all 23 regained function after RRT, 7 (30%) temporarily dialysis independent later (range, 13-63 months). Five had a relapse before restart of RRT. 203 12 (6%) developed during follow-up. These classified as CKD stage 4 5 initial treatment eight becoming dependent.AAV involvement worst probability. multivariate analysis, only major determinants long-term relapses.